Top Markets
Coin of the day
Medigene AG Medigene AG

Medigene AG

MDG1
株式のランク #35468
Medigene AG is a German biotechnology company primarily focused on innovating T... Medigene AG is a German biotechnology company primarily focused on innovating T cell immunotherapies to treat various cancers. Their developmental pipeline includes personalized T cell therapies, particularly T cell receptor-modified T cells, which are progressing through clinical stages to tackle significant unmet medical requirements. Additionally, the firm researches dendritic cell vaccines and T cell-specific monoclonal antibodies. Outside of its oncology efforts, Medigene is actively engaged in developing and bringing to market RhuDex for uses within hepatology and gastroenterology. A key strategic alliance exists with 2seventy bio, Inc., centered on advancing T cell receptors. The company also maintains research collaborations with the Université de Montréal and Cytovant Sciences Co. Ltd., investigating new cancer antigens for immunotherapy applications. Medigene's global presence encompasses operations across Europe, the United States, Asia, and various other international territories. Founded in 1994, the company's headquarters are located in Munich, Germany.
株価
$0.14942078
最終同期: 2025-05-15
時価総額
$3.86M
変化(1日)
0.10%
変化(1年)
0.00%
DE
取引 Medigene AG (MDG1)

カテゴリー

Medigene AG(MDG1)の収益
Jun 2024 時点の収益 TTM: $7.99M
Medigene AG の最新の財務報告によると、現在の収益 (TTM) は $7.99M です。2022 年には $33.52M の収益があり、これは 2021 年の $11.90M と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Medigene AG の収益履歴(2004 ~ 2026)
各年末の収益
収益 変化
2026 (TTM) $7.99M 19.85%
2023 $6.67M -80.10%
2022 $33.52M 181.71%
2021 $11.90M 22.09%
2020 $9.75M -17.36%
2019 $11.79M 35.46%
2018 $8.71M -5.48%
2017 $9.21M 113.45%
2016 $4.32M 28.15%
2015 $3.37M -77.88%
2014 $15.22M 46.65%
2013 $10.38M 34.07%
2012 $7.74M 160.02%
2011 $2.98M 0.59%
2010 $2.96M -94.55%
2009 $54.28M 16.25%
2008 $46.70M 44.83%
2007 $32.24M -19.79%
2006 $40.20M 73.97%
2005 $23.11M 36.31%
2004 $16.95M 0.00%
同業他社の収益
企業 収益 収益の差
$12.62B 157,814.80%
US
$6.02B 75,219.06%
NL
- -
CH
- -
KR
$10.11B 126,373.78%
BE